Search research articles
Contact Us
Filters
Showing results (161-170 of 175) with videos related to
Page
of 18
Sort By:
Molecular Cancer Therapeutics
|
July 31, 2021
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Joanne M Munck, Valerio Berdini, Luke Bevan, et al.
Blood Advances
|
December 7, 2019
End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain
Ann T Farrell, Julie Panepinto, C Patrick Carroll, et al.
Trials
|
January 24, 2018
Overnight auto-adjusting continuous airway pressure + standard care compared with standard care alone in the prevention of morbidity in sickle cell disease phase II (POMS2b): study protocol for a randomised controlled trial
Jo Howard, April E Slee, Simon Skene, et al.
Molecular Cancer Therapeutics
|
March 26, 2017
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Timothy P S Perera, Eleonora Jovcheva, Laurence Mevellec, et al.
Haematologica
|
October 15, 2020
Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients
Paul Telfer, Josu De la Fuente, Mamta Sohal, et al.
The Lancet. Haematology
|
February 8, 2024
Diagnosis and management of pyruvate kinase deficiency: international expert guidelines
Hanny Al-Samkari, Nadine Shehata, Kelly Lang-Robertson, et al.
Journal of Medicinal Chemistry
|
April 9, 2026
From KRAS<sup><i>G12D</i></sup> to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
Xiaoshen Ma, David L Sloman, Timothy J Henderson, et al.
Hepatology (Baltimore, Md.)
|
September 13, 2019
EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks
Laurent Gouya, Paolo Ventura, Manisha Balwani, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors
Young Shin Cho, Hayley Angove, Christopher Brain, et al.
The New England Journal of Medicine
|
June 11, 2020
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Manisha Balwani, Eliane Sardh, Paolo Ventura, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 175) with videos related to
Sort By:
Page
of 18
Molecular Cancer Therapeutics
|
July 31, 2021
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Joanne M Munck, Valerio Berdini, Luke Bevan, et al.
Blood Advances
|
December 7, 2019
End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain
Ann T Farrell, Julie Panepinto, C Patrick Carroll, et al.
Trials
|
January 24, 2018
Overnight auto-adjusting continuous airway pressure + standard care compared with standard care alone in the prevention of morbidity in sickle cell disease phase II (POMS2b): study protocol for a randomised controlled trial
Jo Howard, April E Slee, Simon Skene, et al.
Molecular Cancer Therapeutics
|
March 26, 2017
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Timothy P S Perera, Eleonora Jovcheva, Laurence Mevellec, et al.
Haematologica
|
October 15, 2020
Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients
Paul Telfer, Josu De la Fuente, Mamta Sohal, et al.
The Lancet. Haematology
|
February 8, 2024
Diagnosis and management of pyruvate kinase deficiency: international expert guidelines
Hanny Al-Samkari, Nadine Shehata, Kelly Lang-Robertson, et al.
Journal of Medicinal Chemistry
|
April 9, 2026
From KRAS<sup><i>G12D</i></sup> to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
Xiaoshen Ma, David L Sloman, Timothy J Henderson, et al.
Hepatology (Baltimore, Md.)
|
September 13, 2019
EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks
Laurent Gouya, Paolo Ventura, Manisha Balwani, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors
Young Shin Cho, Hayley Angove, Christopher Brain, et al.
The New England Journal of Medicine
|
June 11, 2020
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Manisha Balwani, Eliane Sardh, Paolo Ventura, et al.
Page
of 18